(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 April 2018 (26.04.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/073725 A1

(51) International Patent Classification:
A61K 35/74 (2015.01) *A61P 13/02* (2006.01)
A61K 38/16 (2006.01) *G01N 33/50* (2006.01)
A61P 13/00 (2006.01)

(21) International Application Number:
PCT/IB2017/056413

(22) International Filing Date:
16 October 2017 (16.10.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1617548.1 17 October 2016 (17.10.2016) GB

(71) Applicant: **LINNANE PHARMA AB** [SE/SE]; Slottsgatan 32, 21133 Malmo (SE).

(72) Inventors: **SVANBORG, Catharina**; Slottsgatan 32, 21133 Malmo (SE). **FILENKO, Nina**; Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Solvegatan 23, 223 62 Lund (SE). **AMBITE, Ines**; Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Solvegaten 23, 223 62 Lund (SE).

(74) Agent: **GREAVES, Carol**; C.P.Greaves & Co, 80 Church Road, Winscombe Somerset BS25 1BP (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2018/073725 A1

(54) Title: INHIBITOR OF RNA POLYMERASE II

(57) Abstract: An inhibitor of RNA polymerase II is described, wherein said inhibitor is selected a moiety which targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. Particular examples of such inhibitors are polypeptides expressed by a gene selected from IldD, IldR, nlpD or rfaH of a bacterial species, such as a commensal bacteria or asymptomatic carrier, or a variant of said protein. Inhibitors may be based upon bacterial Sigma S or NplD proteins. These inhibitors are useful in therapies, to suppress protein expression. Thus they may be used as immunosuppressants, anti-inflammatory or anti- infection agents.